NCT02344563已完成4 期
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Meropenem In Healthy Volunteers(Meropenem Intravenous Injection) After Intravenous Infusion
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 14
- 主要终点
- Adverse events and incidences
研究概览
简要总结
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of meropenem (meropenem intravenous injection 0.5 g) after intravenous infusion in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male or female subjects between 20-45 years of age.
- •Body weight within 80-120% of ideal body weight and higher than or equal to 50 kg for male subjects and 45 kg for female subjects.
- •Ideal body weight (kg) = [height (cm) - 80] × 0.7 for male subjects
- •Ideal body weight (kg) = [height (cm) - 70] × 0.6 for female subjects
- •Acceptable medical history and physical examination including:
- •no particular clinically significant abnormality in X-ray and ECG results within six months prior to study. no particular clinical significance in general disease history within two months prior to study.
- •Acceptable vital signs (within normal limits or considered by the investigator or physician to be of no clinical significance) at screening, which includes pulse rate, blood pressure and body temperature.
- •Acceptable clinical chemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to study, which includes AST (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride (TG).
- •Acceptable hematology (within normal range or considered by the investigator or physician to be of no clinical significance) within two months prior to study, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets.
- •Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to study, which includes pH, blood, glucose, ketones, bilirubin and protein.
- •Female subjects of childbearing potential practicing an acceptable method of birth control from at least seven days prior to study until the end of study as judged by the investigator(s) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy performed on the subject).
- •Have signed the written informed consent to participate in the study.
排除标准
- •A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
- •A clinically significant illness or surgery within four weeks prior to study (as determined by the investigator).
- •History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years.
- •History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant.
- •Known or suspected history of drug abuse within lifetime as judged by the investigator.
- •History of alcohol addiction or abuse within last five years as judged by the investigator.
- •Have a personal history or family history of drug allergy.
- •Subjects demonstrating a positive meropenem skin test screen prior to the study.
- •Evidence of chronic or acute infectious diseases.
- •Female subjects demonstrating a positive urine pregnancy screen prior to study.
- •Female subjects who are currently breastfeeding.
- •Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks prior to study. Examples of inducers include: piperidines, carbamazepine, dexamethasone and rifampin. Examples of inhibitors include: cimetidine, diphenhydramine, fluvastatin, methadone and ranitidine.
- •Taking any prescription medications within four weeks or any nonprescription medications (excluding flu vaccination) within two weeks prior to study.
- •Use of any investigational drug within four weeks prior to study.
- •Donating more than 250 mL of blood within two months prior to study or donating plasma (e.g. plasmapheresis) within two weeks prior to study.
- •Any other medical reason as determined by the clinical investigator.
研究组 & 干预措施
Meropem
Experimental
0.5g/vial,one vial
干预措施: Meropem (Drug)
Meropem
Experimental
0.5g/vial,one vial
干预措施: Mepem (Drug)
Mepem
Active Comparator
0.25g/vial ,two vials
干预措施: Meropem (Drug)
Mepem
Active Comparator
0.25g/vial ,two vials
干预措施: Mepem (Drug)
结局指标
主要结局
Adverse events and incidences
时间窗: predose to 6 hours post dose
次要结局
- Pharmacokinetic parameters(pre dose to 6 hours post dose)
研究者
相似试验
已完成
4 期
Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)Chemotherapy-induced Nausea and Vomiting, ProphylaxisNCT04585412Yung Shin Pharm. Ind. Co., Ltd.16
Unknown
4 期
Evaluate Bioequivalence of Burotam (1/1 g/Vial)Infectious DiseasesNCT05654090Yung Shin Pharm. Ind. Co., Ltd.14
已完成
4 期
Evaluate Bioequivalence of Micafungin (50mg/Vial)Invasive CandidiasisNCT05496725Yung Shin Pharm. Ind. Co., Ltd.14
尚未招募
4 期
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Parecoxib After Intravenous Bolus of Parecoxib in Healthy Volunteers Under Fasting ConditionsPost-operative PainBioequivalence Study in Healthy SubjectsNCT06600282Yung Shin Pharm. Ind. Co., Ltd.14
已完成
4 期
Evaluate Bioequivalence of Voriconazole(200mg/Vial) .Antimycotic for Systematic UseNCT04552353Yung Shin Pharm. Ind. Co., Ltd.14